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Background: Population-based research
on vitamin D has increased dramatically in
recent years. Such studies are typically
reliant on assay procedures to measure
reliable and comparable levels of 25-
hydroxyvitamin D [25(OH)D] concentra-
tions. Methods: Concentrations of 25(OH)
D3 and 25(OH)D2 were measured using
LC-MS/MS in 5,915 participants (aged
31 years) of Northern Finland Birth Cohort
1966. Blood samples were assayed in
batches over a course of 18 months. As
anomalies were present in the measure-
ments, 200 samples were reassayed
using Diasorin RIA. Agreement between
measurements was assessed by Passing–
Bablok regression and limits of agreement
(LoA). To harmonize LC-MS/MS with Dia-
sorin RIA measurements, formulae were
derived from the LoA. Results: Concentra-
tions measured by LC-MS/MS were much
higher than those measured by Diasorin
RIA, with a mean difference of 12.9 ng/ml.
Constant variation was evident between
batch measurements after log transforma-
tion. Statistical formula was applied sepa-
rately for each batch of LC-MS/MS
measurements, enabling us to remove
both the constant and proportional bias
that was evident prior to the transforma-
tion. Conclusion: Despite the introduction
of schemes/programs to improve accuracy
of assays to measure 25(OH)D, signiﬁcant
differences can still happen. In these
instances, methods to harmonize mea-
surements based on a relatively small
number of replicates can be successfully
applied to establish conﬁdence and to
enable between-study comparisons. J.
Clin. Lab. Anal. 00:1–10, 2016. © 2016
The Authors Journal of Clinical Laboratory Analysis
Published by Wiley Periodicals, Inc.
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INTRODUCTION
Epidemiological research on vitamin D has increased
dramatically in recent years as the role of vitamin D in
health is suspected to be broad and far reaching (1).
However, there are significant discrepancies between
procedures used to estimate vitamin D status (2, 3).
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Vitamin D is a prohormone and is mostly obtained
through skin synthesis from UVB exposure, and as
such shows strong seasonal trends (4–6). Vitamin D
can be obtained in two isoforms, and while UVB
exposure-related synthesis will always lead to forma-
tion of cholecalciferol (D3) (6), in diet or dietary sup-
plements, vitamin D can also exist as egrocalciferol
(D2) (7). Vitamin D status can be estimated by mea-
suring total circulating 25-hydroxyvitamin D (25(OH)
D) concentrations, which is the result of the combina-
tion of hydroxylated forms of vitamin D2 and D3 (8).
There are a variety of assay techniques available to
measure 25(OH)D concentrations and some have the
ability to measure the two forms 25(OH)D2 and 25
(OH)D3 (2). Reliable measures across techniques are
essential to have confidence in the concentrations for
clinical practice and to allow comparison across
research studies, such as the prevalence rates of vita-
min D deficiency/sufficiency. The International Vita-
min D External Quality Assessment Scheme (DEQAS)
was established in 1989 with the aim to “monitor the
performance of individual laboratories” (9). Participat-
ing laboratories receive a certificate if 80% of their
results from the five quarterly samples are within 30%
of the all-laboratory trimmed mean (ALTM) (9). The
Vitamin D Standardization Program (VDSP) was
recently established to promote the need for accurate
and comparable 25(OH)D measurements and has a
focus on large national surveys (10). A protocol is
being developed by the VDSP to standardize 25(OH)D
concentrations from past surveys, which can entail
reanalyzing banked sera in a certified laboratory and
developing an equation to harmonize past results with
recent sera results.
In 2008, we measured 25(OH)D2 and 25(OH)D3 in
5,915 participants of the 1966 Northern Finland Birth
Cohort (NFBC1966) (11) using a liquid chromatogra-
phy-mass spectrometry technique (LC-MS/MS). LC-
MS/MS is an automated system with high throughput
and is able to measure separately 25(OH)D2 and 25
(OH)D3 (12). It is an ideal procedure for a population
study and accordingly is becoming frequently used
(13). However, after receiving the results we suspected
that there were some measurement anomalies in the
results obtained by LC-MS/MS on NFBC1966 sam-
ples, as suggested by the very high average 25(OH)D
concentrations in this Nordic population. To validate
the measurements we systematically selected a subsam-
ple of 200 participants and reanalyzed these samples
using a common kit method, Diasorin RIA (14). We
then assessed the limits of agreement (LoA) between
the two methods and the DEQAS results for the labo-
ratory used. On the basis of the limits we sought to
statistically harmonize the LC-MS/MS measures to
Diasorin RIA and justify the transformation through
seasonal trends and vitamin D dietary supplement
information.
METHODS
The NFBC1966 surveyed births in the year 1966
in Finland’s northern provinces of Oulu and Lap-
land (15). The original cohort included over 12,000
deliveries and the survivors have been followed to
adulthood. In 1997, cohort members residing in Fin-
land with known addresses (n = 11,541) were invited
to participate in the postal questionnaire. A subse-
quent invitation to a clinical examination was sent
out to the participants of the postal questionnaire
residing in the regions of Oulu and Lapland, and in
the capital city Helsinki. Of those who responded to
the postal questionnaire, 70% (n = 5,915) consented
to a medical examination and had a stored blood
sample.
In 2008, the frozen serum samples were defrosted
and the 25(OH)D2 and 25(OH)D3 concentrations were
measured using LC-MS/MS. Data were received at
four stages, the first in March 2008 and the last in
August 2009, and the batches were correlated with
original date of storage in the Finnish laboratory in
1997. In total, 5,608 participants had measurements of
25(OH)D concentrations. From each of the four
batches we systematically selected 50 samples over a
range of the 25(OH)D3 and 25(OH)D2 concentrations
for replication with the Diasorin (Stillwater, MN) RIA
(a radioimmunoassay with a 125I-labeled tracer). Dur-
ing the period of study sample assessment (March
2008–August 2009), the laboratory took part in five
rounds of DEQAS evaluations, returning results using
LC-MS/MS for all five samples which were sent each
time. Internal Quality Assurance samples were
included at the front and back of each assay. The
materials, solution, preparation and LC-MS/MS sys-
tem used are detailed below.
Materials and Chemicals
25(OH) Vitamin D2 (25(OH)D2) (cat no. 17937) and
25(OH) Vitamin D3 (25(OH)D3) (cat no. H4014) were
obtained from Sigma Chemical Company (Gillingham,
Dorset, UK) and the internal standard of 26,27 hex-
adeuterium 25(OH)D3 was purchased from Synthetica
AS, Oslo, Norway. HPLC grade methanol, propan-2-ol,
acetonitrile and tetrahydrofuran were obtained from
VWR. Ultrapure deionized water (>18.2 MΩ/cm) was
obtained from a Millipore (Watford, Hertfordshire,
UK) AFS 50 EDI unit. Isolute C18(EC) 200 mg 3 ml
reservoirs were purchased from Kinesis Ltd (St Neots,
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Cambridgeshire, UK). A stream of nitrogen was pro-
vided by a Peak Scientific nitrogen generator, at 40°C in
a Techne Dryblock DB3 (Sigma Chemical Company).
Stock Solutions, Calibration Standard Solutions
and Control Samples
Individual calibrator stock solutions (50 mg/l) of
each metabolite were prepared in ethanol, and their
concentrations checked using a Cary 1E double beam
spectrophotometer (Varian, Walton on Thames, Sur-
rey, UK), using molar absorptivities at 264 nm (1 cm
path length) of 19,400 and 18,300 for 25(OH)D2 and
25(OH)D3, respectively. From these primary stock cali-
brators, an intermediate combined calibrator was pre-
pared by diluting 100 ll of stock 25(OH)D2 and
200 ll of stock 25(OH)D3 in 25 ml of 0.9% saline. An
eight-point working calibration curve was then pre-
pared in 22% bovine albumin (Lorne Laboratories,
Lower Earley, Berkshire, UK), to cover the range up
to 59.7 ng/ml for 25(OH)D2 and 183 ng/ml for 25
(OH)D3. Endogenous concentrations of 25(OH)D2 and
25(OH)D3 present in the bovine albumin were elec-
tronically compensated by the Quanlynx software
(Waters, Elstree, Hertfordshire, UK). Working stan-
dards are prepared freshly with each batch. Internal
standard was prepared by dissolving 5 mg d6 25(OH)
D3 in 200 ml methanol/propan-2-ol. A further dilution
of 1:1,000 in methanol/propan-2-ol (9:1 v/v) was made
to obtain a working concentration of 125 ng/ml.
Sample Preparation
Samples were prepared for analysis by thawing, mixing
and recentrifuging, to remove any fibrin debris. One
milliliter of sample, calibrator, or quality control mate-
rial was pipetted into 10 ml screw top glass tubes. To this
was added 1 ml of working internal standard. Contents
were vortex mixed thoroughly for at least 30 s. Then
2 ml of acetonitrile was added and again vortex mixed
for at least 30 s. Tubes were left at 4°C for 1 h before
centrifugation at 2,000 9 g for 10 min. Supernatants
were transferred to 13 9 100 mm disposable glass tubes
and placed in the sample zone of the Gilson ASPEC
XL4 (Anachem, Luton, UK) and protected from natural
sunlight. The XL4 processed four samples simultane-
ously in approximately 12 min. The instrument sequen-
tially conditioned the C18 solid-phase extraction
cartridges (SPE) in the disposable enrichment cartridge
(DEC) zone with 3 ml of methanol followed by 3 ml of
water, to firstly activate and then condition the SPE prior
to sample introduction. Three milliliters of sample
extract was then introduced onto the SPE followed by a
wash with 2.5 ml of 50:50 methanol:water. Elution of 25
(OH)D2 and 25(OH)D3 was achieved with 3.0 ml of
10% tetrahydrofuran in acetonitrile. The eluate was
dried at 40°C under a stream of nitrogen. Dry extract
was reconstituted in 100 ll of 75% methanol/water and
vortex mixed for 10 s, prior to transferring to a 150 ll
conical microvial and loading into the Aquity sample
racks. Extracts were stable for up to 1 week at 4°C.
LC-MS/MS System
The integrated HPLC system used to separate the
peaks of interest was a Waters Acquity Ultra Perfor-
mance Liquid Chromatography system (Elstree, Hert-
fordshire, UK). Chromatographic separation was
achieved using a Waters SunFire C18 (Elstree, Hert-
fordshire, UK) (3.5 lm 100 mm 9 2.1 mm id) analyti-
cal column fitted with a guard column. Column life
was improved by fitting a 10 mm C18 guard column.
Column temperature was maintained at 40°C. A
Waters Premier XE (Elstree, Hertfordshire, UK) with
a Z spray source, in ESI positive MRM mode with a
source temperature maintained at 130°C, desolvation
temperature at 250°C, gas flow of 950 l/h, and argon
collision gas set at 0.3 ml/min was used for mass
detection. QuanLynx software was used to calculate
relative retention time for peak identification and peak
area ratios with internal standardization for quantita-
tion. Mobile phase A contained 2 mmol/l ammonium
acetate (VWR) in 0.1% formic acid (Fluka Chemical
Company; Sigma-Aldrich). Mobile phase B contained
2 mmol/L ammonium acetate in methanol containing
0.1% formic acid. A binary step gradient was used to
clean the column of any late eluting peaks. Elution of
the vitamins was achieved using 84% B at 0.4 ml/min
for 3.5 min then switching to 100% B for a further
minute before returning to 84% B. Injection interval
was set to 5.5 min, allowing 1 min for re-equilibration
of the column before the next injection. Solvent divert
was used to allow data acquisition to take place
between 1.2 and 3.5 min. Eluent was then introduced
into a Waters Premier XE (Elstree, Hertfordshire, UK)
tandem mass-spectrometer fitted with an electrospray
ionization source. The sample tray area was main-
tained at 15°C. Quantitation MRM transitions were
401.1 > 383.2, 413.2 > 395.2, and 407.1 > 107.1 for 25
(OH)D3, 25(OH)D2, and d6 25(OH)D3, respectively.
Diasorin RIA was obtained from the manufacturer
(Diasorin) and the procedure for use was followed as
described in the pack insert.
Vitamin D Dietary Supplements
The postal questionnaire sent to participants of the
31-year survey asked “How often do you use the
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following medication?. . . Vitamins or trace elements
(1) Not at all, (2) Sometimes, (3) Regularly or continu-
ally. . .” and to list all medicines taken at present with
strength and dose. In the coding of the questionnaire
each of the participants’ medicine was given with an
associated Anatomical Therapeutic Chemical (ATC)
code (16). Vitamins were coded with A11 “Vitamins”
or A12 “Mineral Supplements.” For all supplements
that were listed under the two ATC codes, a Google
search was performed to see if they contained a vita-
min D2 or D3 compound and quantity. If this was not
clear from the distributer or company website, emails
were sent asking for information. Two more subse-
quent emails were sent to the same email address and
any other contact emails found on the websites if a
reply was not received within a few weeks. The medi-
cine listing was double checked for misspellings and
missclassified ATC codes.
Statistical Methods
We assessed the agreement between the methods and
the DEQAS ALTM using Passing–Bablok regression,
which does not make distributional assumptions regard-
ing the data (17). Further investigation was done by
assessing the LoA as outlined by Bland and Altman
(18). The LoA of the measurements were interrogated
by plotting the difference between the two methods of
measurement (as denoted by Di = y1iy2i, where y1 and
y2 are the respective methods for i = 1. . .N pairs of mea-
surements) against the average of the measurements [as
denoted by Ai = (y1iy2i)/2]. To compensate for
increases in variability over increasing magnitude,
the natural log transformation was used. The log-
transformed measures were reinterrogated using LoA to
identify potential outliers, and this was also stratified by
the stages (batches) that the measures were received
from the laboratory.
Evidence for non-constant difference was assessed
by using linear regression of the difference between
measures adjusted for the mean of the measures
(Eqn. 1).
Di ¼ kþ lAi þ ei;where eiN 0; s2
  ð1Þ
The absolute residuals from the model were used in
a linear regression model adjusted for the mean of the
measures to assess for evidence of non-constant vari-
ance (18). As a non-constant difference was evident for
the mean but not for the variance, the LoA were con-
verted into a prediction formula to harmonize the LC-
MS/MS measurements to the Diasorin RIA method
(19). The prediction formula from one method to
another (Eqn. 2) is calculated from the coefficients
estimated in the regression with differences in means
(Eqn. 3) (19).
y20 ¼ a2=1 þ b2=1y10  2 r2=1 ð2Þ
a2=1 ¼ kð1þl=2Þ
b2=1 ¼ ð1l=2Þð1þl=2Þ
r2=1 ¼ sð1þl=2Þ
ð3Þ
The prediction formulae were calculated for the
sample and again individually by the batches (Eqn. 4).
A-Jun2008 : yRIA ¼0:59þ0:70yLCMS=MS2 ð0:30Þ
B-Nov2008 : yRIA¼1:15þ0:60yLCMS=MS2 ð0:24Þ
C-Mar2009 : yRIA¼1:37þ0:50yLCMS=MS2 ð0:28Þ
D-Apr2009 : yRIA¼0:34þ0:86yLCMS=MS2 ð0:28Þ
ð4Þ
Agreement between the harmonized and Diasorin
RIA measures was assessed using Passing–Bablok
regression. Finally, to compare the effect of harmo-
nization, the monthly variation was inspected and the
effect of vitamin D diet supplement on total 25(OH)D
was examined by regressing on the log-transformed
LC-MS/MS, Diasorin RIA, and harmonized LC-MS/
MS measures adjusting for season. The analysis was
done using the software Analyse it (version 2.20) (20)
and Stata (version 12) (21).
RESULTS
One obvious outlier was identified examining results
from Passing–Bablok regression comparing the labora-
tory submitted samples to DEQAS and the DEQAS
ALTM. The values from all other DEQAS samples
submitted from the laboratory using the LC-MS/MS
were very close to the ALTM. Excluding the one out-
lying observation had only a minor difference to the
relationship and we found no evidence of constant or
proportional bias (P-value>0.1, Fig. 1). The perfor-
mance of the LC-MS/MS based on internal standards
was fair with %CV for 25(OH)2D2 12.1% at 9.2 nmol/l,
9.1% at 24.8 nmol/l, 4.8% at 52.8 nmol/l, and 3.9%
at 158.5 nmol/l. For 25(OH)2D3 %CV was 15.5% at
6.1 nmol/l, 5.8% at 19.6 nmol/l, 4.3% at 58.1 nmol/l,
and 3.6% at 124.5 nmol/l.
Comparing the measures in the replicated sample
from LC-MS/MS and Diasorin RIA, we observed a
constant and proportional bias with a mean difference
of 12.9 ng/ml (P-value ≤ 0.0001) (Fig. 2A). A non-
constant difference was seen in the untransformed and
natural log-transformed measures (P-values ≤ 0.0001
for both, Fig. 2B, C). Five observations were seen out-
side of the upper 99% LoA (Fig. 2C) and these
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observations were excluded from harmonization equa-
tions for the sample.
Investigating the sample by the batches that they
were received in from the laboratory, we again saw the
five outlying observations and excluded a further addi-
tional observation from batch B (Fig. 3B) from the
calculations with the batches. We found there was no
evidence for non-constant variance in the natural log-
transformed measures across the sample and when
analyzed as separate batches (P-value ≥0.11 for indi-
vidual batches and sample). Given, the constant vari-
ance we were able to calculate the prediction formulae
to harmonize the LC-MS/MS measures by extension
of the LoA.
After harmonizing the LC-MS/MS measures using a
prediction formula for the sample and individual for-
mulae for the batches (Eqn. 4), the constant and pro-
portional bias in concentrations measured by LC-MS/
MS compared to Diasorin RIA that was evident
before transformation was removed (Fig. 4). The best
agreement between the assays methods was obtained
by carrying out the harmonization in batches. Further-
more, the seasonal pattern observed for the harmo-
nized measures demonstrated a clearer pattern than
the non-harmonized LC-MS/MS measures, with the
pattern appearing visually similar to the Diasorin RIA
measures (Fig. 5). The median values and prevalence
of 25(OH)D above 40 ng/ml in the harmonized 25
(OH)D concentrations were similar with concentra-
tions measured by Diasorin RIA (6.0% and 6.6%,
respectively, Table 1), and notably reduced from the
45.5% before transformation. Consistent with the
(a)
(b)
(c)
Fig. 2. Positive bias in 25-hydroxyvitamin D concentrations mea-
sured by liquid chromatography-mass spectrometry technique (LC-
MS/MS) compared to Diasorin RIA. (A) Passing–Bablok regres-
sion (dashed line) compared to identity (solid line). (B) Mean dif-
ference in concentrations (ng/ml, solid line) with limits of
agreement (95% LoA). (C) Mean difference after log transforma-
tion with limits of agreement (95% LoA dashed line; 99% LoA
short dashed line).
Fig. 1. 25-hydroxyvitamin D concentrations as measured from the
Vitamin D External Quality Assessment Scheme (DEQAS) samples
in the study laboratory compared to the mean from all participating
laboratories (DEQAS all-laboratory trimmed mean [ALTM]). Pass-
ing–Bablok regression (dashed line) compared to identity (solid line).
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lower mean and narrower range in the values, vitamin
D supplementation was associated with slightly smaller
increases in 25(OH) D concentrations with the harmo-
nized measures compared with the non-harmonized
measures, however, confidence limits were also some-
what tighter (Fig. 6).
DISCUSSION
In our study, we were able to adjust 25(OH)D con-
centrations measured by LC-MS/MS to be in line with
a single replicate measured from the Diasorin RIA
using an extension of LoA. The logic we have used to
achieve harmonization is similar to a protocol that is
being developed by VDEP to harmonize 25(OH)D
from large studies (10). The harmonization has been
based on regression equations that extend the LoA
(19), this is also similar to the procedures proposed by
the National Center for Environmental Health to
address measurement issues related to variability in the
Diasorin assay in NHANES surveys (22). By harmo-
nizing the measurements of 25(OH)D, the prevalence
rates of 25(OH)D deficiency/sufficiency and effect sizes
found with health outcomes in this large population
survey can be more readily compared with rates from
other studies.
In general, it has been reported that 25(OH)D con-
centrations measured by Diasorin RIA and LC-MS/
MS procedures are in close agreement (reported corre-
lation 0.91–0.98) (23–27). Close agreement has been
reported in a range of conditions, including studies in
participants with relatively high 25(OH)D2 concentra-
tions (23), with no detectable 25(OH)D2 concentra-
tions (25), with detectable levels of C-3 epimer of 25
(OH)D (27), and with elevated vitamin D binding pro-
tein levels (26). However, moderate and possibly non-
linear agreement between the procedures has also been
observed (28, 29), illustrating potential for method-
ological issues with regard to the use of different
assays.
Fig. 3. The difference in the log-transformed 25-hydroxyvitamin D concentrations measured by LC-MS/MS and Diasorin RIA by batch (A-
Jun 2008, B-Nov/Dec 2008, C-Mar 2009, D-Apr 2009). The solid black line is the mean log difference, dashed line 95% LoA, and short
dashed line 99% LoA.
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For the NFBC1966 measurements of 25(OH)D, it
remains unclear why there were anomalies in the mea-
surements from LC-MS/MS. The blood samples were
stored in a freezer for 11 years prior to 25(OH)D
measurement, however, some authors have reported
that concentrations of 25(OH)D in serum and plasma
are unaffected by long-term storage and iterations of
freeze-thaw cycles (30, 31). However, we are able to
discount the possibility of storage-related interference
by unknown metabolites in our samples affecting
measures obtained by LC-MS/MS. There have been
concerns about 3-epi-25(OH)D3 interference in 25
(OH)D3 measurement by LC-MS/MS (32). While this
could have had some effect on 25(OH)D3 measures in
our study, it is likely to be of limited importance
given the low circulating concentrations of 3-epi-25
(OH)D3 in adults. A potential source of error is the
use of in-house calibrators and internal standardiza-
tion in the LC-MS/MS procedure (33). To this end,
US agencies and government departments have devel-
oped a serum-based reference material and it is hoped
that this will improve assay comparability (2). Since
the reporting of DEQAS data in July 2005, the level
of recovery 25(OH)D concentrations has improved
compared with ALTM, and the proportion of labora-
tories using LC-MS/MS has increased at the same
time (34, 35). However, the use of ALTM as the
standard has its own issues. The ALTM has moved
away from the gold standard (gas chromatography-
mass spectrometry) as more methods are used to
measure 25(OH)D (35). A passing result by DEQAS
does not deem a method as accurate, but as being
relatively similar compared with other laboratories
that used that method (36, 37).
In our study, we resampled 200 participants with the
Diasorin RIA for several reasons. Diasorin RIA has
been used extensively in RCTs, clinics, and research
studies and has been commercially available for a long
time (37). As with LC-MS/MS it requires a skilled
technician to run the assay, however, it has been con-
cluded that in terms of convenience, speed, turn-
around, and cost, a well-known immunoassay is a
reasonable choice (38). In some studies, Diasorin RIA
assay has been reported to recover up to 100% of 25
(OH)D2 and 25(OH)D3 concentrations (39). Neverthe-
less, it is recognized that Diasorin RIA assay is not
fully exempt from issues of 25(OH)D2 recovery (22,
(a) (b)
Fig. 4. Linear association in 25-hydroxyvitamin D concentrations measured by liquid chromatography-mass spectrometry technique (LC-
MS/MS) and Diasorin RIA after statistical harmonization. The solid black line is the relationship from Passing–Bablok regression and the
dashed line is the identity. (A) LC-MS/MS measures harmonized by single formula; (B) LC-MS/MS measures harmonized by batch-specific
formulae.
Fig. 5. Monthly variation in 25(OH)D concentrations for liquid
chromatography-mass spectrometry technique (LC-MS/MS) (un-
transformed, light grey), Diasorin RIA (mid-grey), and harmonized
LC-MS/MS (dark grey) measures. Shown as the mean with 25th and
75th percentiles (box), range given by error bars.
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40). As we have demonstrated in this study, a direct
comparison of agreement against Diasorin RIA (as an
example of an alternative, commonly used assay) is a
possible solution when the use other references such as
the DEQAS results is impractical, as was previously
done by one of the authors (41). However, despite
achieving better agreement between the methods by
the statistical harmonization of 25(OH)D concentra-
tions, any use of these data for developing population
health guidelines should be done with caution.
The prediction equations used to harmonize the
methods were based on one measurement (per sample)
from each assay. Another option may have been to
use prediction equations from Deming regression, but
this would have assumed that there was a fixed value
for the ratio of variances (19). In an earlier study, it
was observed that at low 25(OH)D concentrations,
LC-MS/MS gave higher values than Diasorin RIA,
whereas at high levels LC-MS/MS measures were
lower than Diasorin RIA (28). To investigate whether
deviations in the agreement between LC-MS/MS and
Diasorin in the NFBC1966 measures were dependent
on the concentrations, prediction equations were
derived after stratifying the sample by levels of 25(OH)
D2 and 25(OH)D3 (data not shown). However, stratifi-
cation by level did not improve the prediction equa-
tions. Nevertheless, it is possible that information at
the high extremes of the 25(OH)D concentrations may
have been lost by harmonizing as overall variation has
been reduced.
In conclusion, measures of 25(OH)D concentra-
tions in large population surveys are a vital source
of information for research and the forming of
public health messages. In this study we have illus-
trated the uses of a statistical procedure that can be
used to harmonize the distribution of 25(OH)D con-
centrations across assays, which will improve the
ability to use general cut-offs to indicate low/high
concentrations.
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TABLE 1. Description of LC-MS/MS, Diasorin RIA, and Harmonized LC-MS/MS 25-Hydroxyvitamin D Measures, ng/ml in
the Replicated Sample (n = 200)
Median (IQR)
Supplements
<10 ng/ml % (n) >40 ng/ml % (n)
Yes
Median (IQR)
No
Median (IQR)
LC-MS/MS
Total 25(OH)D 37.2 (24.0, 52.0) 41.3 (31.0, 54.0) 36.9 (22.5, 52.0) 6.5 (13) 45.5 (91)
25(OH)D2 3.2 (1.6, 10.7) 17.5 (3.3, 24.3) 2.7 (1.4, 6.4) NA NA
25(OH)D3 28.6 (16.8, 45.5) 21.7 (15.0, 29.4) 30.4 (17.2, 46.6) NA NA
Diasorin RIA
Total 25(OH)D 25.7 (18.6, 32.8) 29.3 (23.2, 34.0) 25.6 (17.6, 32.8) 4.1 (8) 6.6 (13)
Harmonized LC-MS/MS
Total 25(OH)D 26.2 (18.8, 32.8) 27.4 (25.2, 36.8) 24.9 (18.0, 32.1) 6.5 (13) 6.0 (12)
Fig. 6. The association of vitamin D supplementation with 25-
hydroxyvitamin D concentrations measured by liquid chromatogra-
phy-mass spectrometry technique (LC-MS/MS) (untransformed, light
grey), Diasorin RIA (mid-grey) and harmonized LC-MS/MS (dark
grey) from a linear regression model adjusted for season. Ninety-five
percent confidence intervals given by error bars.
J. Clin. Lab. Anal.
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